Toshinori Agatsuma

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate et al. · Cancer Science · 2016 · 715 citations · Full text

Medicine, Oncology, Pharmacology +17

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida et al. · Molecular Cancer Therapeutics · 2018 · 273 citations

Medicine, Oncology, Pharmacology +17

Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents

Masao Yoshida, Ichiro Hayakawa, Noriyuki Hayashi et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 202 citations

Medicine, Medicinal Chemistry, Pharmacology +11

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai et al. · Clinical Cancer Research · 2019 · 174 citations

Medicine, Oncology, Pharmacology +15